ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,308.13
0.09%
Dow Jones
39,806.77
-0.49%
US Dollar vs MXN
16.5368
-0.11%
Brent Oil
83.125
-0.48%
Bitcoin
70,956.62
-0.69%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. USOTC
  6. Aeolus Pharmaceuticals Inc (CE) (AOLS)

  7. Aeolus Pharmaceuticals Inc (CE) (AOLS) Noticias

AOLS

Aeolus Pharmaceuticals (CE) (AOLS)

Aeolus Pharmaceuticals Inc (CE)
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:USOTC:AOLS
FechaHoraFuenteTítuloSímboloCompañía
22/12/201715:53Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
14/08/201716:09Edgar (US Regulatory)Quarterly Report (10-q)USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
24/03/201710:51Edgar (US Regulatory)Current Report Filing (8-k)USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
14/02/201710:17Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
30/01/201716:06Edgar (US Regulatory)Amended Annual Report (10-k/a)USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
30/12/201615:55Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
20/12/201616:28Edgar (US Regulatory)Securities Registration Statement (s-1)USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
20/12/201616:25Edgar (US Regulatory)Annual Report (10-k)USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
16/05/201616:09Edgar (US Regulatory)Amended Quarterly Report (10-q/a)USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
19/04/201616:10Edgar (US Regulatory)Information Statement - All Other (definitive) (def 14c)USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
23/03/201615:49Edgar (US Regulatory)Proxy Statement - Other Information (preliminary) (pre 14c)USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
16/02/201605:01Edgar (US Regulatory)Notice of Effectiveness (effect)USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
12/02/201615:32Edgar (US Regulatory)Securities Registration Statement (s-1/a)USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
18/12/201505:05Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
15/12/201514:24Edgar (US Regulatory)Amended Current Report Filing (8-k/a)USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
17/02/201515:32Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
01/07/201406:30MarketwiredAeolus Announces Additional Data Demonstrating Efficacy of AEOL 10150 as a Medical Countermeasure Against Exposure to Nerve A...USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
18/06/201409:39MarketwiredAeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal CEES Model of Mustard Gas Skin ExposureUSOTC:AOLSAeolus Pharmaceuticals Inc (CE)
02/06/201415:32Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
02/06/201407:00MarketwiredAeolus Pharmateucticals to Present at LD Micro Invitational ConferenceUSOTC:AOLSAeolus Pharmaceuticals Inc (CE)
15/05/201418:03MarketwiredAeolus Announces Second Quarter Fiscal Year 2014 Financial Results and Achievements in Lung-ARS Development ProgramUSOTC:AOLSAeolus Pharmaceuticals Inc (CE)
28/03/201411:24Edgar (US Regulatory)Registration of Securities by Certain Investment Companies. Declaration of Election Rule 24f-2 Notice (24f-2nt)USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
28/03/201411:24Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
14/02/201416:30MarketwiredAeolus Announces First Quarter Fiscal Year 2014 Financial ResultsUSOTC:AOLSAeolus Pharmaceuticals Inc (CE)
14/02/201416:00Edgar (US Regulatory)Mutual Fund Summary Prospectus (497k)USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
14/02/201416:00Edgar (US Regulatory)Definitive Materials Filed by Investment Companies. (497)USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
13/02/201406:30MarketwiredAeolus Announces Process Improvements and Positive 18 Month Stability Results for AEOL 10150 in New FormulationUSOTC:AOLSAeolus Pharmaceuticals Inc (CE)
10/02/201406:30MarketwiredAeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal Model of Lung Radiation Exposure; Models ...USOTC:AOLSAeolus Pharmaceuticals Inc (CE)
23/01/201409:52MarketwiredAeolus Receives Orphan Drug Designation for AEOL 10150 From U.S. FDAUSOTC:AOLSAeolus Pharmaceuticals Inc (CE)
23/12/201307:00MarketwiredAeolus Announces Fiscal Year 2013 Financial ResultsUSOTC:AOLSAeolus Pharmaceuticals Inc (CE)
 Showing the most relevant articles for your search:USOTC:AOLS

Su Consulta Reciente

NASDAQ
QQQ
Invesco QQQ Trust Series 1
USI
USTECH100
US Tech 100
FX
EURMXN
Euro vs MXN
COIN
BTCUSD
Bitcoin
NASDAQ
AMZN
Amazon.com
FX
EURUSD
Euro vs US Dollar
NYSE
CVX
Chevron
USOTC
BASFY
BASF (QX)
AMEX
XLV
Health Care Select Sector
COIN
SOLUSD
Solana
NYSE
VZ
Verizon Communications
AMEX
XLF
Financial Select Sector
SPI
SP500
S&P 500
NYSE
MCD
McDonalds
NYSE
JPM
JP Morgan Chase
NYSE
DIS
Walt Disney
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados